Publications

Murepavadin (POL7080)

All posters of the European Congress of Clinical Microbiology and Infections Diseases (ECCMID) are accepted. Further information: ESCMID eLibrary

Poster; European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 22-25, 2017 (PDF)

Pharmacokinetics of Murepavadin (POL7080) and Amikacin in a drugdrug interaction study in healthy subjects

Poster; European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 22-25, 2017 (PDF)

Pharmacokinetic and efficacy analysis of Murepavadin (POL7080) co-administered with standard-of-care (SoC) in a phase II study in patients with ventilator-associated pneumonia (VAP) due to suspected or documented Pseudomonas aeruginosa infection

Poster; European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 22-25, 2017 (PDF)

Population pharmacokinetics modeling of Murepavidin (POL7080) and simulation of target attainment in a population with ventilator-associated pneumonia due to infection with Pseudomonas aeruginosa

Poster; European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 22-25, 2017 (PDF)

Catabolism and excretion of the anti-pseudomonal peptidomimetic Murepavadin (POL7080) in humans

Poster; European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 22-25, 2017 (PDF)

In vitro drug transporter interaction studies with the outer membrane protein targeting antibiotic Murepavadin (POL7080)

Poster; European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016 (PDF)

Pharmacokinetics of POL7080 co-administered with standard of care in patients with ventilator-associated pneumonia due to suspected or documented Pseudomonas aeruginosa infection

Poster; European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31-April 3, 2012 (PDF)

Phase I (multiple ascending dose) study with the novel Pseudomonas aeruginosa antibiotic POL7080 in healthy volunteers

Poster; European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 7-10, 2011 (PDF)

Phase I study with the novel Pseudomonas aeruginosa antibiotic POL7080 in healthy volunteers

OMPTA – new antibiotics platform

Scientific publication; Current Opinion in Chemical Biology, June 2017 (Link)

Protein epitope mimetic macrocycles as bio-pharmaceuticals
A. Luther, K. Moehle, E. Chevalier, G. Dale, D. Obrecht

POL7001

All posters of the European Congress of Clinical Microbiology and Infections Diseases (ECCMID) are accepted. Further information: ESCMID eLibrary

Scientific publication; American Society for Microbiology (ASM); June 13, 2016 (Link)

Efficacy of the novel antibiotic POL7001 in preclinical models of Pseudomonas aeruginosa pneumonia

Poster; European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 22-25, 2017 (PDF)

POL7001 is highly efficacious in the murine neutropenic lung infection model

Balixafortide (POL6326)

Below posters are accepted by ASCO and all authors to be published here.

Poster; American Society of Clinical Oncology (ASCO), June 3-7, 2016 (PDF)

Dose escalation of POL6326 in combination with Eribulin in HER2-negative relapsed metastatic breast cancer (MBC) patients

Poster; American Society of Clinical Oncology (ASCO), June 2-7, 2017 (PDF)

Phase Ib study of the combination of Balixafortide (a CXCR4 inhibitor) and Eribulin in HER2-negative metastatic breast cancer patients